semaglutide news oct 26 2025 today october Half of people stop taking popular weight-loss drug within a year, study finds semaglutide news october 2025 – Switching between weight-loss medications -

Employer coverage is rapidly expanding - 44% of large employers now cover GLP-1s for obesity, with 21% more considering coverage within three years

L-Lysine 500 mg Highlights: 500 mg of L-Lysine per tablet

It is more often discussed as a repair-focused compound because of its proposed effects on inflammation, tissue healing, angiogenesis, and mucosal protection

Heart failure Dapagliflozin and empagliflozin are indicated for the treatment of symptomatic chronic heart failure regardless of ejection fraction in adults with or without type 2 diabetes

These may indicate serious complications requiring urgent assessment